CD28 and acute myeloid leukemia: More conventional strategies such as CD123CAR (autologous CD123CAR-CD28-CD3ζ-EGFRt) have demonstrated antileukemic efficacy with acceptable toxicities in seven patients with R/R AML who had undergone prior alloHSCT (NCT02159495).304,305